恶性高热2020:麻醉医师协会指南
该指南由麻醉医师协会制定,更新了恶性高热的危机管理推荐,并扩展至疑似病例急性反应逆转后的临床诊断、监测、设备、沟通、家属咨询及转诊确认诊断等实践指导,同时回顾了围术期风险患者的识别与预防措施。
要点
- 恶性高热是遗传易感者暴露于挥发性麻醉药或琥珀胆碱后发生的致命性高代谢综合征。
- 早期识别并立即积极治疗是关键,否则可能致命。
- 指南扩展了急性反应逆转后的监测、ICU管理、沟通及转诊确认诊断的实践指导。
核心结论
- 恶性高热是遗传易感者暴露于强效吸入麻醉药或琥珀胆碱时发生的进行性危及生命的高热反应,早期识别和积极治疗至关重要。
研究设计与样本
- 麻醉医师协会制定的指南,基于背景信息更新危机管理推荐,并提供临床诊断及疑似病例急性反应后管理的详细指导。
主要发现
- 恶性高热无特异性临床特征,易感者暴露于强效吸入麻醉药或琥珀胆碱有发病风险。
- 指南扩展了急性反应逆转后的护理与监测、手术室及ICU的设备与复苏措施、沟通与团队合作、患者及家属咨询以及转诊确认诊断的指导。
临床怎么用
- 麻醉医师应熟悉恶性高热的早期识别和危机管理,并掌握急性反应逆转后的监测、设备准备、沟通及转诊流程。
- 对遗传易感患者进行围术期管理时需采取相应预防措施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Malignant hyperthermia is defined in the International Classification of Diseases as a progressive life-threatening hyperthermic reaction occurring during general anaesthesia. Malignant hyperthermia has an underlying genetic basis, and genetically susceptible individuals are at risk of developing malignant hyperthermia if they are exposed to any of the potent inhalational anaesthetics or suxamethonium. It can also be described as a malignant hypermetabolic syndrome. There are no specific clinical features of malignant hyperthermia and the condition may prove fatal unless it is recognised in its early stages and treatment is promptly and aggressively implemented. The Association of Anaesthetists has previously produced crisis management guidelines intended to be displayed in all anaesthetic rooms as an aide memoire should a malignant hyperthermia reaction occur. The last iteration was produced in 2011 and since then there have been some developments requiring an update. In these guidelines we will provide background information that has been used in updating the crisis management recommendations but will also provide more detailed guidance on the clinical diagnosis of malignant hyperthermia. The scope of these guidelines is extended to include practical guidance for anaesthetists dealing with a case of suspected malignant hyperthermia once the acute reaction has been reversed. This includes information on care and monitoring during and after the event; appropriate equipment and resuscitative measures within the operating theatre and ICU; the importance of communication and teamwork; guidance on counselling of the patient and their family; and how to make a referral of the patient for confirmation of the diagnosis. We also review which patients presenting for surgery may be at increased risk of developing malignant hyperthermia under anaesthesia and what precautions should be taken during the peri-operative management of the patients.
引用
- Hopkins PM, Girard T, Dalay S, et al. Malignant hyperthermia 2020: Guideline from the Association of Anaesthetists. Anaesthesia. 2021. PMID: 33399225. doi:10.1111/anae.15317
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。